May 14, 2001
Taisho Develops Chinese Weiyangning Stomach Medication
Taisho Pharmaceutical Co., Ltd. (president: Akira Uehara) is planning to release a new herbal medication for stomach and digestive problems on May 16. Chuyaku Ichoyaku contains Weiyangning , an ingredient based on traditional herbal remedies from China.
Taisho developed the new medication based on medical research into Weiyangning conducted at the Xiyuan Hospital, China Academy of Traditional Chinese Medicine. Researchers at the academy analyze the scientific merits of traditional treatments and practices, including herbal medicines, yaoshan (Chinese health food), acupuncture and moxibustion, and qigong, and seek present-day applications. The research center developed Weiyangning from the Chinese herbal medicine Huangqijianzhongtang in 1985.
Taisho's new medication draws on the effectiveness of Weiyangning to deliver relief for a wide variety of stomach problems for the middle- and upper-age brackets. Stomach ailments are more common among the elderly because, in addition to overall deterioration, the membranes in the stomach thin and weaken.
Taisho plans to acquire over-the-counter approval for the Chuyaku Ichoyaku, which is the first new development resulting from Taisho's research agreement with the China Academy of Traditional Chinese Medicine in 1986. Taisho has strong ties with China. In 1984, the pharmaceutical company formed with an alliance Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College to test and develop natural ingredients for medical applications, and has a similar contract with Sichuan Industrial Institute of Antibiotics of the State Pharmaceutical Administration of China, signed in 1990, to research microorganisms. In 1998, Taisho began sales of Lipovitan in China through Shanghai Taisho Guan Sheng Yuan Co., Ltd., with the chief purpose of promoting sales of its quasi-drug drinks.